HTP

Wejo Wins 2022 BIG Innovation Award

Retrieved on: 
Wednesday, January 18, 2023
Public Policy, Government, Public Safety, Automotive Manufacturing, Environment, Data Analytics, Technology, Logistics, Supply Chain Management, Manufacturing, Mobile, Wireless, Construction & Property, Urban Planning, Public Transport, Autonomous Driving, Vehicles, Fleet Management, Professional Services, Trucking, State, Local, Automotive, EV, Electric Vehicles, Transport, Software, Internet, Smart mobility, Microsoft, JT Group Limited, Heart, Organization, Safety, General Motors, City, RTTI, University, Traffic, HTP, Mobile phone

Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility for Good™ and cloud and software solutions for connected, electric and autonomous vehicle data, today announces it has been named a winner in the 2023 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility for Good™ and cloud and software solutions for connected, electric and autonomous vehicle data, today announces it has been named a winner in the 2023 BIG Innovation Awards presented by the Business Intelligence Group.
  • “Since establishing Wejo in 2014, innovation has been at the heart of our mission to unlock the value in autonomous, electric and connected vehicle data,” said Richard Barlow, founder and CEO of Wejo.
  • In 2022, Wejo launched two innovative, high-performance solutions aimed at bettering the world through connected vehicle data.
  • “We are thrilled to be honoring Wejo as they are leading by example and improving the lives of so many.”
    Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards.

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

Retrieved on: 
Friday, January 6, 2023
HTP, Precision medicine, HTG, Therapy, Pharmaceutical industry

TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

Key Points: 
  • Cash and cash equivalents of $12.2 million as of December 31, 2022
    TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.
  • Actual results may differ materially from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that the company’s financial results are finalized, and such changes could be material.
  • In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2022, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.
  • The company expects to announce full 2022 financial results in advance of its quarterly conference call in March 2023.

The Worldwide Heated Tobacco Products (HTP) Industry is Projected to Reach $7.9 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Tobacco, Retail, Online, Restaurant, Leaf, Anxiety, Death, Mouth, Tobacco, Research, COVID-19, Smoke, Nicotine, HTPS, Mask, HTP, US, Animal

The global heated tobacco products (HTP) market was valued at US$4.16 billion in 2021.

Key Points: 
  • The global heated tobacco products (HTP) market was valued at US$4.16 billion in 2021.
  • The market value is projected to grow to US$7.97 billion by 2027.
  • The volume of global heated tobacco products (HTP) market, was at 4180.37 ton in 2021.
  • The volume of the global heated tobacco products market is projected to grow to 7452.80 ton by 2027.

CHAR Technologies Acknowledges Canada and Ontario Announce More Than $11.3M Investment For CHAR Technologies Thorold, Ontario, Renewable Energy Production Facility

Retrieved on: 
Tuesday, December 13, 2022
The Honourable, Ministry of the Environment, Conservation and Parks, Park, Conservation, Sale, Welland Canal, Hub, RNG, Environment, Investment, Methane, Innovation, Science and Economic Development Canada, TSX Venture Exchange, Forestry, Natural gas, Natural Resources, Ministry of Economic Development, Job Creation and Trade, CHAR, Ministry of Natural Resources and Forestry, Pyrolysis, Carbon, Government, Government of Ontario, Engineering, News, Biomass, HTP, Wood, Federal Economic Development Agency for Southern Ontario, Greenhouse, Blockchain.com, Municipal government in Canada, Plastic, Climate change, Federal Economic Development Initiative for Northern Ontario, Economic development, Automotive Supplier Innovation Program, Renewable energy, Fossil fuel, Animal, Niagara Centre
Key Points: 

    HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

    Retrieved on: 
    Tuesday, December 6, 2022
    RNA, GEP, Validation, 2021 Essex County Council election, ASH, Roswell Park Comprehensive Cancer Center, HTG, SVP, Research, COVID-19, Non-Hodgkin lymphoma, Diagnosis, Prednisolone, Cancer, Treatment, Rituximab, Society, Precision medicine, Therapy, Drug discovery, Mortality, HTP, First Line, Genmab, BeiGene, CD19, Medicine, Cedars-Sinai Medical Center, Transcriptome, Determinant, Disease, Perelman School of Medicine at the University of Pennsylvania, Lymphocyte, DLBCL, Risk, Pharmaceutical industry, Medical imaging, Medical device, Vincristine, Cyclophosphamide, Patient, Doxorubicin
    Key Points: 

      HTG Molecular Diagnostics Reports Third Quarter 2022 Results

      Retrieved on: 
      Thursday, November 10, 2022
      GLOBE, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Nasdaq, Human, Risk, Intention, HTP, Sale, Drug discovery, Diagnosis, Therapy, Precision medicine, RNA, SEC, Safety, HTG, Senior, Security (finance), Industry, COVID-19, Medical device, Pharmaceutical industry, Fine chemical

      TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the quarter ended September30, 2022 and provided recent business highlights.

      Key Points: 
      • TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the quarter ended September30, 2022 and provided recent business highlights.
      • We have achieved our third quarter 2022 milestones and remain on track to begin partnering conversations for our first target and indication by the end of 2022, said John Lubniewski, Chief Executive Officer and Director at HTG.
      • Third Quarter 2022 Financial Highlights:
        Revenue for the quarter ended September30, 2022 was $1.3 million, compared with $2.5 million for the same period in 2021, and was comprised entirely of product and product-related services revenue.
      • Net loss per share was $(0.41) for the quarter ended September30, 2022 compared with $(0.60) for the third quarter of 2021.

      Hybrid Technology Partners, a leading priority ERP partner in Ireland, climbs up the SME ladder with the Bronze Vendor Award from Lumenia, a national ERP H2H event in Ireland.

      Retrieved on: 
      Monday, November 7, 2022
      Cloud, CFO, Financial management, Motor vehicle, Priority, Business development, Industry, Data management, App Store (iOS/iPadOS), TEL, Enterprise resource planning, Solution, Organization, ERP, HTP, Grade (consulting), Risk management, Online shopping, Lumenia, Data

      Lumenia offered the participants a unique opportunity to observe leading ERP solutions pitted against each other.

      Key Points: 
      • Lumenia offered the participants a unique opportunity to observe leading ERP solutions pitted against each other.
      • During the virtual event, 9 ERP software solutions competed for the title of Best Vendor Demonstration Virtual Event 2022, addressing Production and financial management capabilities and demonstrating their unique selling points.
      • Our latest ERP HEADtoHEAD event, where Hybrid presented an excellent Priority ERP demonstration, had a record number of organizations attending, all potential buyers of ERP solutions.
      • "We are very proud of this award, considering the exponentially growing Cloud ERP ecosystem in Europe, and UK and Ireland in particular.

      Wejo Recognized with “Traffic Tech Solution of the Year” by the AutoTech Breakthrough Awards

      Retrieved on: 
      Wednesday, November 2, 2022
      Construction & Property, Data Management, Technology, Public Safety, EV, Electric Vehicles, Trucking, Autonomous Driving, Vehicles, Public Policy, Government, Transport, Urban Planning, Automotive, Software, Logistics, Supply Chain Management, Networks, Public Transport, Vehicle Technology, CEO, Organization, Intelligence, Work, Industry, City, JT Group Limited, Congestion, Travel, Transport, RTTI, Government, Safety, NASDAQ, Company, HTP, Smart mobility, Solution, Mobile phone, Satellite navigation device

      Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility for Good and cloud and software solutions for connected, electric and autonomous vehicle data, today announced it has been named the Traffic Tech Solution of the Year by AutoTech Breakthrough Awards.

      Key Points: 
      • Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility for Good and cloud and software solutions for connected, electric and autonomous vehicle data, today announced it has been named the Traffic Tech Solution of the Year by AutoTech Breakthrough Awards.
      • This is also the second consecutive year that Wejo has been recognized by AutoTech Breakthrough Awards, having been named Overall Connected Company of the Year in 2021.
      • As we continue to develop and implement Smart Mobility for Good products and services, we are honored to have these solutions recognized this year and Wejo for a second year by AutoTech Breakthrough Awards.
      • The annual AutoTech Breakthrough Awards program conducts the industrys most comprehensive analysis and evaluation of automotive and transportation technologies.

      HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

      Retrieved on: 
      Wednesday, October 26, 2022
      NGS, Therapy, SEC, HTG, Drug discovery, Gene expression profiling, Oncology, Commercial Operating System (COS), DNA, Private Securities Litigation Reform Act, Diagnosis, Nasdaq, Cancer, U.S. Securities and Exchange Commission, HTP, Risk, Physician, Diet, RNA, Gene expression, Patient, Technology, Industry, COO, GLOBE, AI, RNA-Seq, Biomarker, Precision medicine, Molecular biology, Gene, Medical device, Fine chemical, Medical imaging

      Through this collaboration, samples collected by OmiCure will be sent to HTGs VERI/O laboratory in Tucson, Arizona for processing.

      Key Points: 
      • Through this collaboration, samples collected by OmiCure will be sent to HTGs VERI/O laboratory in Tucson, Arizona for processing.
      • HTP utilizes the proprietary HTG EdgeSeq system, requiring only a fraction of the tissue biopsy material used by other systems to analyze nearly 20,000 genes.
      • OmiCure leverages Onco KEM, an AI-transcriptional-based therapeutic recommendation-tool, which has been tested in an international multi-center clinical trial.
      • It has the power to analyze clinically relevant cancer biomarkers from DNA, RNA and protein profiles, from both solid and liquid biopsies.

      HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

      Retrieved on: 
      Wednesday, October 12, 2022
      U.S. Securities and Exchange Commission, Drug design, HTP, Therapy, Risk, SEC, Diagnosis, RNA, Nasdaq, Precision medicine, HTG, Technology, Senior, Private Securities Litigation Reform Act, Drug discovery, Industry, Safety, GLOBE, White paper, White, COVID-19, Fine chemical, Pharmaceutical industry

      Significant milestone progress made during the period included the advancement of machine-learning components of the transcriptome-informed drug discovery and design platform and the continued generation of internal, proprietary data supporting the training set.

      Key Points: 
      • Significant milestone progress made during the period included the advancement of machine-learning components of the transcriptome-informed drug discovery and design platform and the continued generation of internal, proprietary data supporting the training set.
      • We have made significant strides during the third quarter, further advancing our transcriptome-informed drug discovery platform and solidifying our first planned targets utilizing HTGs novel approach, said Dr. Stephen Barat, Senior Vice President of Therapeutics at HTG.
      • A cornerstone of the Therapeutics business, the HTG Transcriptome Panel (HTP) was launched with commercial availability in August 2021.
      • Further information regarding HTGs transcriptome-informed drug design and discovery platform is included in the White Papers published by HTG earlier in the year, which can be found here .